Trending Stock News

argenx SE (ARGX) Reaches $90.22 After 4.00% Down Move; Gran Tierra Energy (NYSEAMERICAN:GTE) SI Increased By 3.24%

Gran Tierra Energy Inc. (NYSEAMERICAN:GTE) Logo

The stock of argenx SE (NASDAQ:ARGX) is a huge mover today! The stock decreased 3.11% or $2.9 during the last trading session, reaching $90.22. About 210,089 shares traded or 92.65% up from the average. argenx SE (NASDAQ:ARGX) has risen 340.78% since June 20, 2017 and is uptrending. It has outperformed by 328.21% the S&P500. Some Historical ARGX News: ; 18/04/2018 – Argenx Non-Deal Roadshow Scheduled By Wedbush for Apr. 25; 24/04/2018 – argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting; 26/03/2018 – ARGENX: EC ORPHAN STATUS FOR ARGX-113 FOR MYASTHENIA GRAVIS; 12/04/2018 – ARGENX NV ARGX.BR – MAY RECEIVE FURTHER REGULATORY AND CLINICAL MILESTONE PAYMENTS UP TO APPROX. EUR 100MM AS WELL AS ROYALTIES ON NET SALES OF ANY PRODUCT; 09/05/2018 – ARGENX NV ARGX.BR – EXPECTED MILESTONE: PROGRESS ARGX-113 INTO PHASE 3 CLINICAL DEVELOPMENT IN GENERALIZED MG BEFORE END OF YEAR; 09/04/2018 – REG-argenx appoints Keith Woods as Chief Operating Officer; 12/04/2018 – argenx to receive third preclinical milestone payment from collaboration with LEO Pharma – Milestone associated with CTA approval for ARGX-112; 26/03/2018 – ARGENX SE: ARGENX ORPHAN DRUG DESIGNATION FOR ARGX-113 FOR; 24/04/2018 – ARGENX NV ARGX.BR – TOTAL AND PATHOGENIC IGG REDUCTION CORRELATES WITH DISEASE SCORE IMPROVEMENTS; 25/04/2018 – Argenx at Non-Deal Roadshow Hosted By Wedbush TodayThe move comes after 6 months negative chart setup for the $2.96 billion company. It was reported on Jun, 20 by Barchart.com. We have $86.61 PT which if reached, will make NASDAQ:ARGX worth $118.24 million less.

Gran Tierra Energy Inc (NYSEAMERICAN:GTE) had an increase of 3.24% in short interest. GTE’s SI was 3.82 million shares in June as released by FINRA. Its up 3.24% from 3.70 million shares previously. With 1.49 million avg volume, 3 days are for Gran Tierra Energy Inc (NYSEAMERICAN:GTE)’s short sellers to cover GTE’s short positions. The SI to Gran Tierra Energy Inc’s float is 1.25%. The stock increased 2.22% or $0.07 during the last trading session, reaching $3.22. About 768,165 shares traded. Gran Tierra Energy Inc. (NYSEAMERICAN:GTE) has risen 31.09% since June 20, 2017 and is uptrending. It has outperformed by 18.52% the S&P500. Some Historical GTE News: ; 27/03/2018 – BallenIsles Charities Foundation sets another fundraising record — awarding more than Half-a-Million Dollars in Financial Gran; 10/05/2018 – Gran Colombia Gold 1Q Adj EPS 46c; 06/03/2018 BMW Reveals a Gran Coupe Concept That’s More Sport Than Sedan; 01/05/2018 – Gran Tierra Energy 1Q EPS 5c; 20/04/2018 – GRAN COLOMBIA GOLD RECEIVES REQUISITE SECURITYHOLDER APPROVAL AND CONSENTS AND EXPECTS TO CLOSE PREVIOUSLY ANNOUNCED DEBT FINANCING ON APRIL 30, 2018; 27/03/2018 – Gran Colombia Gold 4Q EPS 11c; 18/05/2018 – GRAN TIERRA ENERGY INC GTE.TO : CIBC RAISES TARGET PRICE TO C$5 FROM C$4; 20/04/2018 – Gran Colombia Gold Receives Requisite Securityholder Approval and Consents and Expects to Close Previously Announced Debt Finan; 14/05/2018 – Entertain Weekly: Exclusive first look at Betty Buckley as Gran’ma in Preacher; 14/05/2018 – Gran Colombia Gold Completes Redemptions of 2020 and 2024 Debentures

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer. The company has market cap of $2.96 billion. The companyÂ’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It currently has negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

More notable recent argenx SE (NASDAQ:ARGX) news were published by: Seekingalpha.com which released: “Argenx’s efgartigimod shows encouraging action in mid-stage pemphigus vulgaris study” on June 20, 2018, also Nasdaq.com with their article: “argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating …” published on June 14, 2018, Seekingalpha.com published: “Argenx announces data from phase 1 study of ARGX-113” on June 14, 2018. More interesting news about argenx SE (NASDAQ:ARGX) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” published on June 20, 2018 as well as Nasdaq.com‘s news article titled: “argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2018” with publication date: June 12, 2018.

Gran Tierra Energy Inc., an independent energy company, engages in the acquisition, exploration, development, and production of gas and oil properties in Colombia, Peru, and Brazil. The company has market cap of $1.26 billion. As of December 31, 2016, the firm had total proved undeveloped reserves of 14.9 million barrels of oil equivalent , including 10.4 MMBOE in Colombia and 4.5 MMBOE in Brazil. It currently has negative earnings.

argenx SE (NASDAQ:ARGX) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *